Biogen Pays $100M In New Isis Pharma Alliance
Biogen Idec will pay $100 million upfront to acquire exclusive rights to Isis Pharmaceuticals Inc.'s gene-altering technology, the companies said Monday, in a collaboration that seeks to develop new medications for...To view the full article, register now.
Already a subscriber? Click here to view full article